title: Tumor immunotargeting using innovative radionuclides.
abstract: This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality.
authors: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. francoise.bodere@chu-nantes.fr.|Department of Nuclear Medicine, University Hospital, Nantes 44093, France. francoise.bodere@chu-nantes.fr.|Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO)-Site Gauducheau, Saint-Herblain 44805, France. francoise.bodere@chu-nantes.fr.
authors: Françoise
authors: F
authors: Kraeber-Bodéré
authors: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. caroline.rousseau@ico.unicancer.fr.|Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO)-Site Gauducheau, Saint-Herblain 44805, France. caroline.rousseau@ico.unicancer.fr.
authors: Caroline
authors: C
authors: Rousseau
authors: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. cedric.mathieu@chu-nantes.fr.|Department of Nuclear Medicine, University Hospital, Nantes 44093, France. cedric.mathieu@chu-nantes.fr.
authors: Caroline
authors: C
authors: Bodet-Milin
authors: Department of Nuclear Medicine, University Hospital, Nantes 44093, France. cedric.mathieu@chu-nantes.fr.
authors: Cédric
authors: C
authors: Mathieu
authors: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. francois.guerard@univ-nantes.fr.
authors: François
authors: F
authors: Guérard
authors: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. eric.frampas@chu-nantes.fr.|Department of Radiology, University Hospital, Nantes 44093, France. eric.frampas@chu-nantes.fr.
authors: Eric
authors: E
authors: Frampas
authors: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. cedric.mathieu@chu-nantes.fr.|Department of Nuclear Medicine, University Hospital, Nantes 44093, France. cedric.mathieu@chu-nantes.fr.
authors: Thomas
authors: T
authors: Carlier
authors: AMAROC, ONIRIS, Nantes 44300, France. nicolas.chouin@oniris-nantes.fr.
authors: Nicolas
authors: N
authors: Chouin
authors: Physics Department, Groupement d'Intérêt Public Arronax, Nantes 44817, France. ferid.haddad@univ-nantes.fr.
authors: Ferid
authors: F
authors: Haddad
authors: Physics Department, Groupement d'Intérêt Public Arronax, Nantes 44817, France. chatal@arronax-nantes.fr.
authors: Jean-François
authors: JF
authors: Chatal
authors: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. cedric.mathieu@chu-nantes.fr.|Department of Nuclear Medicine, University Hospital, Nantes 44093, France. cedric.mathieu@chu-nantes.fr.
authors: Alain
authors: A
authors: Faivre-Chauvet
authors: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. michel.cherel@univ-nantes.fr.|Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO)-Site Gauducheau, Saint-Herblain 44805, France. michel.cherel@univ-nantes.fr.
authors: Michel
authors: M
authors: Chérel
authors: Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. jacques.barbet@univ-nantes.fr.|Physics Department, Groupement d'Intérêt Public Arronax, Nantes 44817, France. jacques.barbet@univ-nantes.fr.
authors: Jacques
authors: J
authors: Barbet
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003952:Diagnostic Imaging; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D016499:Radioimmunotherapy / Q000379:methods; D011868:Radioisotopes / Q000008:administration & dosage; D011877:Radionuclide Imaging
chemical_list: D000911:Antibodies, Monoclonal; D011868:Radioisotopes